HOWL
Werewolf Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$21.56M
P/E Ratio
—
EPS
$-1.21
Beta
0.41
52W High
$2.38
52W Low
$0.40
50-Day MA
$0.77
200-Day MA
$1.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-41.73M |
| EBITDA | $-54.35M |
| Operating Margin | 0.00% |
| Return on Equity | -161.90% |
| Return on Assets | -42.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.25 |
| Price-to-Book | 1.77 |
| Price-to-Sales (TTM) | 10.21 |
| EV/Revenue | 0.674 |
| EV/EBITDA | 0.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $48.60M |
| Float | $41.23M |
| % Insiders | 5.62% |
| % Institutions | 35.00% |
Historical Volatility
HV 10-Day
84.82%
HV 20-Day
92.36%
HV 30-Day
89.48%
HV 60-Day
98.51%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($4.00 target)
3
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026